Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - women: moderately severe to severe signs of androgenisation. moderately severe/severe forms of hirsutism; moderately severe/severe androgen dependent loss of scalp hair (moderately severe/severe androgenic alopecia); moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenisation. apo-cyproterone acetate 50mg inhibits the influence of male sex hormones which are also produced by the female. it is thus possible to treat diseases in women caused by either increased production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment. if apo-cyproterone acetate 50mg is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of child bearing potential, pregnancy must be excluded at the commencement of treatment and ethinyloestradiol taken as well to ensure contraception. this also promotes regular

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - leuprolide acetate (unii: 37jns02e7v) (leuprolide - unii:efy6w0m8tg) - leuprolide acetate 5 mg in 1 ml - leuprolide acetate injection is indicated in the palliative treatment of advanced prostatic cancer. leuprolide acetate injection is contraindicated in patients known to be hypersensitive to gnrh, gnrh agonist analogs or any of the excipients in leuprolide acetate injection: reports of anaphylactic reactions to gnrh agonist analogs have been reported in the medical literature. leuprolide (loo proe lide) acetate injection read the instructions for use before you start using leuprolide acetate injection and each time you get a refill. there may be new information. this information does not take the place of talking to your doctor about your medical condition or your treatment. your doctor should show you how to draw up leuprolide acetate injection and give the injection the right way before you inject the first time. do not share your syringes with other people, even if the needle has been changed. you may give other people a serious infection or get a serious infection from them.   supplies you will need f

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 5 mg - medroxyprogesterone acetate tablets usp are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. they are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets. medroxyprogesterone acetate is contraindicated in women with any of the following conditions:

United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg - in patients without structural heart disease, flecainide acetate tablets usp are indicated for the prevention of: flecainide acetate tablets usp are also indicated for the prevention of: use of flecainide acetate tablets usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets usp is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets usp, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate tablets usp should not be used in patients with recent myocardial infarction. (see boxed warnings ). use of flecainide acetate tablets usp in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings ). as is the case for other antiarrhythmic agents, there is no evidence from cont

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - fludrocortisone acetate (unii: v47if0pvh4) (fludrocortisone - unii:u0476m545b) - fludrocortisone acetate 0.1 mg - fludrocortisone acetate tablets are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in addison's disease and for the treatment of salt-losing adrenogenital syndrome. fludrocortisone acetate tablets (corticosteroids) are contraindicated in patients with systemic fungal infections and in those with a history of possible or known hypersensitivity to these agents.

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - norethindrone acetate 5 mg - norethindrone acetate tablets, usp is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. norethindrone acetate tablets, usp are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection. - known or suspected pregnancy. there is no indication for norethindrone acetate, usp in pregnancy. (see precautions .) - undiagnosed vaginal bleeding - known, suspected or history of cancer of the breast - active deep vein thrombosis, pulmonary embolism or history of these conditions - active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction) - impaired liver function or liver disease - as a diagnostic test for pregnancy - hypersensitivity to any of the drug components

United States - English - NLM (National Library of Medicine)

county line pharmaceuticals, llc - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg - in patients without structural heart disease, flecainide acetate tablets is indicated for the prevention of - paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide acetate tablets are also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular achycardia (sustained vt), that in the judgment of the physician are life-threatening. use of flecainide acetate tablets for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets, its use shou

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - histrelin acetate (unii: qmg7hld1ze) (histrelin acetate - unii:qmg7hld1ze) - histrelin acetate .99 g in 1 g

United States - English - NLM (National Library of Medicine)

paddock laboratories, llc - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate tablets, usp are indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. patients with hypercalcemia.